Equities
  • Price (EUR)104.56
  • Today's Change-2.32 / -2.17%
  • Shares traded60.00
  • 1 Year change-10.45%
  • Beta1.2211
Data delayed at least 15 minutes, as of Jul 11 2025 16:25 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.

  • Revenue in USD (TTM)6.63bn
  • Net income in USD1.17bn
  • Incorporated1999
  • Employees18.00k
  • Location
    Agilent Technologies Inc5301 Stevens Creek BlvdSANTA CLARA 95051United StatesUSA
  • Phone+1 (408) 345-8886
  • Fax+1 (408) 345-8474
  • Websitehttps://www.agilent.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
A:NYQ since
announced
Transaction
value
Sigsense Technologies IncDeal completed29 Jul 202429 Jul 2024Deal completed-10.22%--
BioVectra IncDeal completed22 Jul 202422 Jul 2024Deal completed-6.45%925.00m
Data delayed at least 15 minutes, as of Jul 11 2025 21:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.